February 21, 2007 – InSightec’s ExAblate 2000, a Magnetic Resonance Imaging (MRI) focused ultrasound device that treats uterine fibroid tumors, is now allowing most patients to find relief within three months of treatment and to return to work within days.
The ExAblate 2000 uses a combination of ultrasound waves and MRIs to image, treat and ablate soft tissue. Treatment typically takes about three or four hours.
March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...
March 31, 2026 
March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...
March 30, 2026 
March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...
March 23, 2026 
March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...
March 17, 2026 
March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...
March 13, 2026 
March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...
March 13, 2026 
Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...
March 09, 2026 
March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...
March 06, 2026 
March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...
March 03, 2026 
March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...
March 03, 2026 